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Abstract
Hyperforin is one of the main bioactive compounds that underlie the antidepressant actions of the med-
icinal plant Hypericum perforatum (St. John’s wort). However, the effects of a chronic hyperforin treatment
on brain cells remains to be fully addressed. The following study was undertaken to further advance
our understanding of the biological effects of this plant extract on neurons. Special attention was given to
its impact on the brain-derived neurotrophic factor (BDNF) receptor TrkB and on adult hippocampal
neurogenesis since they appear central to the mechanisms of action of antidepressants. The consequences
of a chronic hyperforin treatment were investigated on cortical neurons in culture and on the brain of adult
mice treated for 4 wk with a daily injection (i.p.) of hyperforin (4 mg/kg). Its effects on the expression
of the cyclic adenosine monophosphate response element-binding protein (CREB), phospho-CREB
(p-CREB), TrkB and phospho-TrkB (p-TrkB) were analysed by Western blot experiments and its impact
on adult hippocampal neurogenesis was also investigated. Hyperforin stimulated the expression of
TRPC6 channels and TrkB via SKF-96365-sensitive channels controlling a downstream signalling
cascade involving Ca2+, protein kinase A, CREB and p-CREB. In vivo, hyperforin augmented the
expression of TrkB in the cortex but not in the hippocampus where hippocampal neurogenesis
remained unchanged. In conclusion, this plant extract acts on the cortical BDNF/TrkB pathway leaving
adult hippocampal neurogenesis unaffected. This study provides new insights on the neuronal responses
controlled by hyperforin. We propose that the cortex is an important brain structure targeted by
hyperforin.
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Introduction
The medicinal plant Hypericum perforatum, also named
St. John’s wort (SJW), contains nearly two dozen
of bioactive compounds which possess interesting
pharmacological properties including : anti-bacterial,
anti-inflammatory, anti-tumoural and anti-angiogenic
properties (Lorusso et al. 2009; Saddiqe et al. 2010;
Schempp et al. 1999). In addition, SJW extracts have
been shown to possess central nervous system (CNS)
effects and are used as antidepressants (Di Carlo et al.
2001; Linde et al. 1996; Mennini & Gobbi, 2004 ;
Muller, 2003). Although several constituents of SJW
seem to contribute to its therapeutic efficacy
(Chatterjee et al. 1998b), the phloroglucinol derivative
hyperforin is regarded as the main effector (Cervo et al.
2002; Chatterjee et al. 1998a ; Zanoli, 2004). How-
ever, its actions on brain cells and the mechanisms
Address for correspondence : Mr A. Bouron, Laboratoire de Chimie et
Biologie des Me´taux, UMR CNRS 5249, CEA, 17 rue des Martyrs,
38054 Grenoble, France.
Tel. : 00 33 4 38 78 44 23 Fax : 00 33 4 38 78 54 87
Email : alexandre.bouron@cea.fr
* These authors contributed equally to this work.
International Journal of Neuropsychopharmacology, Page 1 of 10. f CINP 2012
doi:10.1017/S146114571100188X
ARTICLE
underlying its putative clinical antidepressant effect
remain poorly characterized. Recently, many cellular
targets of hyperforin have been identified (Beerhues,
2006 ; Medina et al. 2006). For instance, it has been de-
termined that this plant extract controls the activity of
enzymes like microsomal prostaglandin E2 synthase-1
(Koeberle et al. 2011), sirtuins 1 and 2 (Gey et al. 2007),
cyclooxygenase-1 or 5-lipoxygenase (Albert et al.
2002), as well as binding to intracellular receptors like
the pregnane X receptor (Moore et al. 2000) and alter-
ing the expression of genes, e.g. CYP2C genes (Chen &
Goldstein, 2009). Hyperforin has also been shown to
interfere with neurotransmission by inhibiting the re-
uptake of many neurotransmitters and dissipating the
pH gradient of synaptic vesicles. This results in a re-
distribution of monoamines from these vesicles to the
cytoplasmic compartment (Roz & Rehavi, 2004). An-
other interesting characteristic of hyperforin is its
ability to influence the transport of ions. Hyperforin is
a potent blocker of various channels like ionotropic
GABA and glutamate receptors (Chatterjee et al. 1999;
Fisunov et al. 2000; Kumar et al. 2006). Besides these
inhibitory properties, hyperforin is currently known to
activate TRPC6, a Ca2+-conducting channel of the
plasma membrane (Leuner et al. 2007). TRPC6 is the
only channel opened by this plant extract. The hyper-
forin-dependent activation of TRPC6 channels con-
trols various biological processes. For instance, when
chronically applied, hyperforin promotes neurite ex-
tension in the neuronal cell line PC12 (Leuner et al.
2010) and induces the differentiation of keratinocytes
(Muller et al. 2008).
The aim of the present study was to advance our
understanding of hyperforin’s mechanisms of action
on brain cells. In particular, special attention was
given to its impact on the brain-derived neurotrophic
factor (BDNF) receptor TrkB and on adult hippo-
campal neurogenesis since they appear central in the
molecular pathophysiology of depression and in the
pharmacological mechanisms of action of anti-
depressants (Duman &Monteggia, 2006 ; Kozisek et al.
2008; Miguel-Hidalgo & Rajkowska, 2002 ; Sahay &
Hen, 2007). Thus, the question of whether hyperforin
affects the above-mentioned processes was addressed
by using neurons in culture and adult mice chronically
treated with hyperforin. The data collected illustrate
that chronic hyperforin treatment triggers an intra-
cellular signalling pathway that involves the cyclic
adenosine monophosphate (cAMP)-dependent pro-
tein kinase A (PKA) and the transcription factor cAMP
response element-binding protein (CREB), and regu-
lates the expression of the BDNF receptor TrkB and
TRPC6. This hyperforin-dependent cascade critically
depends on the activity of Ca2+-conducting channels
and occurs specifically in the cortex but not in the
hippocampus. Our findings provide new insights into
the neurobiological actions of a chronic hyperforin
treatment on CNS neurons.
Methods
Cell cultures
Primary cultures of cortical neurons were prepared
from embryonic E13 C57BL6/J mice (Bouron et al.
2005). Brains were placed in an ice-cold Ca2+- and
Mg2+-free Hank’s solution to which was added 33 mM
glucose, 4.2 mM NaHCO3, 10 mM Hepes, and 1%
penicillin/streptomycin. Depending on the number
of embryos, 1–3 pregnant mice were used to prepare
one batch of cultured cells. The cortices were pooled
and placed in a sterile 1.5 ml Eppendorf tube before
being dissociated by means of repetitive aspirations
through a sterile and fire-polished Pasteur pipette.
This cell suspension was then filtered through a
40 mm cell strainer (BD Falcon, USA) and plated onto
poly-L-ornithine-treated Petri dishes (Ø 6 cm). Cells
were grown for 3 d in a Neurobasal medium contain-
ing 2% B27, 1% penicillin/streptomycin and 500 mM
glutamine (Bouron et al. 2005). Next, half of this cul-
ture medium was removed and replaced with fresh
Neurobasal medium. The procedures used were ap-
proved by the Ethical Committee of Grenoble
(ComEth) (protocol 7_IRTSV-LCBM-AB-01).
Chronic treatment of C56Bl6/J mice with hyperforin
Twenty-six 5-month-old male C57Bl6/J mice (Charles
River, France) were housed under standard conditions
on a 12-h light/dark cycle (lights on 07:00 hours) with
water and food available ad libitum. Thirteen animals
received a daily intraperitoneal (i.p.) injection of a
fresh hyperforin solution (4 mg of hyperforin/kg body
weight) diluted in a sterile NaCl (0.9%) solution.
Control animals (n=13) were treated with a hyper-
forin-free NaCl solution. After 4 wk of treatment, the
brain of three hyperforin-treated mice and of three
control mice were isolated and placed in an ice-cold
saline solution. They were subsequently used for the
extraction of proteins (see below). The other animals
received two 5-bromo-2k-deoxyurydine (BrdU) injec-
tions at 24-h intervals (25 mg BrdU/animal). After
this, the daily injections of hyperforin (or NaCl) were
repeated for 3 more weeks before intra-cardiac injec-
tion of paraformaldehyde (PFA) and processing of the
brains for analysis of hippocampal neurogenesis (see
below).
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Protein extraction and Western blot analysis
For the in-vivo experiments, proteins from the cortex
and the hippocampus were extracted using Nucleo-
spin RNA/protein kit (Macherey-Nagel, France) fol-
lowed by precipitation with ethanol. Samples were
kept on ice for 30 min and centrifuged at 11 320 g for
30 min at 4 xC. The pellet was resuspended in a buffer
containing 150 mM NaCl, 1% Triton X-100, 0.1% SDS,
0.24% Tris–HCl and 0.5% deoxycholate.
For the in-vitro experiments, hyperforin was added
to the culture medium 5 d after the plating of the
neuronal cells. At that time, the culture medium was
removed and replaced by a fresh Neurobasal medium
containing 1 mM hyperforin (or DMSO, control cells).
The concentration of DMSO was <0.1%. Cells were
subsequently kept for 72 h during which the culture
medium containing hyperforin (or DMSO) was chan-
ged every day. At the end of the 72-h treatment, cells
were harvested and centrifuged for 5 min at 453 g. The
pellet was resuspended in a buffer containing (in mM):
10 Hepes, 3 MgCl2, 40 KCl, 2% glycerol, 1% Triton
X-100, 1% protease inhibitors (Sigma, France), with
a pH of 7.5. The samples were kept on ice for 30 min
and centrifuged at 11 320 g for 30 min at 4 xC before
collecting the supernatant. Proteins were quantified
using the Bio-Rad DC protein assay.
Immunoblotting analyses were performed with
50 mg proteins after separation on a 8% SDS–poly-
acrylamide gel. PVDF membranes were blocked for
2 h in 5% non-fat dry milk. The primary antibodies
used were either anti-TrkB (1 :500, Millipore, USA),
anti-phospho-TrkB (anti-p-TrkB) (1 :200, tebu-bio,
France), anti-CREB (1:1000, Millipore), anti-phospho-
CREB (anti-p-CREB) (1 :1000, Millipore), anti-TRPC6
(1 :200, Alomone Labs) or actin (1 :250, Sigma). Over-
night incubation at 4 xC with the primary antibody
was followed by incubation with a horseradish per-
oxidase-coupled secondary antibody (1 :5000, Bethyl,
USA). Detection of the bands by chemiluminescence
(ECL, Pierce, USA) was achieved using a Fusion Fx7
apparatus (Vilbert Lourmat, France). Quantification of
protein expression was made with ImageJ software :
for a given protein, its expression was normalized to
the level of actin expression.
Adult hippocampal neurogenesis
For these experiments, 10 animals from each group
(i.e. hyperforin-treated and NaCl-treated animals)
were used. Animals were anaesthetized with pento-
barbital. The fixation of the brain was achieved after
an intra-cardiac injection of 4% PFA in PBS (Dupret
et al. 2008). Free-floating sections (40 mm) were
processed in a standard immunohistochemical pro-
cedure in order to visualize BrdU (1 :2000, Accurate
Scientific, USA), phosphorylated histone H3 (pH 3,
1 :2000, Upstate, USA) and doublecortin (DCX, 1 :1000,
Santa Cruz Biotechnology, USA), on alternate one-in-
ten sections. The numbers of immunoreactive (IR) cells
throughout the entire granular layer of the supra-
granular and infragranular blades of the dentate gyrus
(both sides for BrdU and HH3, and the left side for
DCX) were estimated using the optical fractionator
method (Dupret et al. 2007).
Statistical analysis
Throughout this study, data are presented as
means¡S.E.M. The statistical significance of the differ-
ence between the groups was determined using
SigmaStat (version 3.5, Systat Software, USA).
Materials
Tissue culture media were obtained from Invitrogen
(France). BrdU was obtained from Serva (France). All
other reagents were from Sigma-Aldrich (France).
Hyperforin was a kind gift from Dr Willmar Schwabe
GmbH & Co. (Germany). The extract was a mixture of
hyperforin with its homologue adhyperforin (ratio
8 :2), prepared as sodium salts (Tu et al. 2009).
Results
The consequences of a chronic hyperforin treatment
on cell proliferation, cell survival and adult hippo-
campal neurogenesis were analysed in adult mice
after 4 wk of daily i.p. injections (4 mg/kg) of hyper-
forin. The mice then received two injections of BrdU to
label dividing cells followed by a continuous treat-
ment of hyperforin for 3 more weeks. The chronic hy-
perforin treatment had no effect on cell proliferation as
measured by the number of phosphorylated histone
H3 by means of an anti-phospho-histone H3 that re-
cognizes histone H3 when phosphorylated at Ser10 (pH
3, Fig. 1a). The survival of 3-wk-old BrdU-labelled
cells was also not modified (Fig. 1b). As a conse-
quence, neurogenesis, evaluated by the number of
DCX, remained unchanged (Fig. 1c). Thus, under the
experimental conditions used, hyperforin did not
influence hippocampal adult neurogenesis.
The effects of hyperforin on expression of TrkB in
the cortex and hippocampus were also addressed.
Adult mice were chronically treated for 4 wk (4 mg/
kg.d) with hyperforin. This treatment enhanced the
expression of TrkB and p-TrkB in the cortex by nearly
124% and 200% (p<0.05), respectively (Fig. 2a, b).
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The expression of CREB and p-CREB, although
slightly augmented, was nevertheless not different
when compared to their respective controls (NaCl-
treated animals) (p>0.05). In marked contrast to the
cortex, the expression of the above-mentioned pro-
teins in the hippocampus was not modulated by hy-
perforin (Fig. 2a, b). This indicates that hyperforin
exerts tissue-specific responses.
Since hyperforin influences the expression of TrkB
in the cortex but not in the hippocampus, cultures of
cortical neurons were prepared to uncover the me-
chanisms by which this plant extract alters the BDNF
pathway. We first determined whether a chronic ap-
plication of hyperforin changes the expression of
CREB, p-CREB, TrkB and p-TrkB (Fig. 3a). A 72 h
hyperforin treatment enhanced the expression of
CREB, p-CREB and TrkB in cultured cortical neurons
by 70%, 109% and 71%, respectively (p<0.05)
(Fig. 1b). However, p-TrkB remained unaffected.
It was recently shown that a chronic hyperforin
treatment in adult mice influences Zn2+ storage ca-
pacities of brain cells by stimulating the expression of
metallothioneins (Gibon et al. 2011). Since Zn2+ inter-
feres with the activity of the BDNF/TrkB pathway by
activating TrkB independent of its ligand (Huang et al.
2008), we investigated whether the Zn2+ chelator
TPEN could prevent the hyperforin-dependent regu-
lation of p-CREB and TrkB. Cortical neurons in culture
were kept for 72 h with a medium supplemented with
either 1 mM TPEN or 1 mM TPEN+1 mM hyperforin.
With TPEN, hyperforin was still able to enhance the
phosphorylation of CREB (Fig. 3c) showing that Zn2+
does not play a role in regulating the hyperforin-
dependent cascade leading to increases in the ex-
pression of CREB and its phosphorylated form.
However, in the presence of TPEN, hyperforin failed
to up-regulate TrkB expression (Fig. 3d) suggesting
that this metal controls a step in between the trans-
cription factor p-CREB and the expression of TrkB.
Since hyperforin selectively enhances the activity
of the Ca2+-conducting TRPC6 channels, while leav-
ing the other TRPC channels unaffected (Leuner et al.
2007), it is postulated that hyperforin could influence
neuronal properties by regulating the cytosolic
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Fig. 1. Hyperforin does not influence adult hippocampal neurogenesis. Ten control (left panel) and ten treated animals
(middle panel) received, respectively, a daily injection of 0.9% NaCl or 4 mg/kg hyperforin for 4 wk. This treatment was
followed by two injections of 5-bromo-2k-deoxyurydine (BrdU) (at 24-h intervals) and animals were treated for 3 more weeks
with 4 mg/kg hyperforin (or with 0.9% NaCl). Animals were killed and brain slices were immunostained with antibodies
against pH3, BrdU and doublecortin (DCX). Representative photomicrographs with immunostained cells localized in the
dentate gyrus are shown (left and middle panels). The total number of pH3-immunoreactive (IR) (a), BrdU-IR (b) and DCX-IR
(c) cells is also given (right panels). No significant differences were observed between groups for cell proliferation (a), cell
survival (b) and neurogenesis (c). Scale bar, 50 mm.
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concentration of Ca2+. Experiments were performed
to verify whether Ca2+ channels were implicated in
the hyperforin-dependent regulation of TrkB ex-
pression. Cortical neurons were kept in a medium
containing the Ca2+ channel blocker SKF-96365 (5 mM)
alone or SKF-96365 (5 mM)+hyperforin (1 mM). In the
latter case, SKF-96365 was added 10 min before the
addition of hyperforin. In the presence of SKF-96365,
hyperforin did not enhance the phosphorylation of
CREB (Fig. 3c). It also failed to up-regulate the ex-
pression of TrkB (Fig. 3d). The Ca2+ chelator BAPTA-
AM was used to determine whether Ca2+ controls the
phosphorylation of CREB and TrkB expression.
Cortical neurons were thus grown in a medium con-
taining 100 nM BAPTA-AM. Preliminary experiments
showed that depending on the concentration used
(e.g. ato1 mM), a sustained application of BAPTA-AM
resulted in cell loss (not shown). Interestingly, low
concentrations of BAPTA-AM were sufficient to dis-
turb the hyperforin-dependent expression of p-CREB
and TrkB (Fig. 3c, d). These results obtained with SKF-
96365 and BAPTA suggest that Ca2+ is a central com-
ponent, playing a role downstream of hyperforin and
upstream of p-CREB and TrkB. Furthermore, cAMP-
dependent PKA is known to control CREB activity
(Kingsbury et al. 2003; Lonze & Ginty, 2002). Thus,
its involvement in the hyperforin-dependent phos-
phorylation of CREB was investigated. Cells were
incubated with hyperforin (1 mM) or with hyper-
forin+RpcAMP (20 mM), a competitive inhibitor of
PKA (Murray, 2008). Under the latter condition, the
expression of TrkB and p-CREB was not up-regulated
(Fig. 3c, d). Instead, the expression of TrkB and
p-CREB was reduced by 9% and 34%, respectively.
The data summarized in Fig. 3c, d suggest that SKF-
96365-sensitive channels, Ca2+ ions and PKA are
potentially crucial candidates participating in the
hyperforin-dependent regulation of TrkB expression.
The results obtained from the SKF-96365 and
BAPTA experiments suggest that hyperforin acts on
Ca2+-conducting channels. TRPC6 channels are the
sole Ca2+ channels activated by hyperforin (Leuner
et al. 2007). It is important to note that the expression of
hippocampal TRPC6 channels increases from post-
natal day 0 to postnatal day 14 and then strongly
declines, with a weak expression observed during
adulthood (Tai et al. 2008). This developmental regu-
lation in the expression pattern of hippocampal
TRPC6 channels could explain, at least partially, the
lack of responsiveness of this brain structure to hyper-
forin. The expression of TRPC6 channels in the adult
mouse brain was investigated by Western blotting
(Fig. 4a). In the cortex of control animals, the level of
TRPC6 expression was around four times higher than
that observed in the hippocampus (Fig. 4b). In ad-
dition, hyperforin treatment increased the expression
of TRPC6 in the cortex (p<0.05) (Fig. 4b) but not in the
hippocampus (p>0.05) (Mann–Whitney) (Fig. 4b).
Discussion
SJW is one of the most commonly used medicinal
plant (Wills et al. 2000). Since the first meta-analysis of
Linde et al. (1996) showing that extracts of SJWwere as
effective as standard antidepressants for the treatment
of some forms of mood disorders (Linde et al. 1996),
the usefulness of this medicinal plant has been docu-
mented (Di Carlo et al. 2001; Stevinson & Ernst, 1999).
Although several constituents of SJW seem to con-
tribute to its antidepressive action, the phloroglucinol
derivative hyperforin is considered as its main effector
(Cervo et al. 2002; Chatterjee et al. 1998a). Due to its
recognized clinical efficacy, SJW is regarded as an
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Fig. 2. Hyperforin regulates the expression of TrkB in the
cortex but not in the hippocampus of adult mice. (a)
Representative Western blots showing the expression of
TrkB, p-TrkB, CREB and p-CREB in control animals (NaCl,
n=3) and in animals treated for 4 wk with hyperforin (i.p.,
4 mg/kg.d, n=3). (b) The panel shows the changes in the
expression level of TrkB, p-TrkB, CREB and p-CREB in both
groups in the cortex and (black bar) and the hippocampus
(white bar). * p<0.05 (Kruskal–Wallis one-way analysis of
variance followed by a Holm–Sidak test).
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alternative treatment for depression. However, the
mechanisms by which it acts on neuronal functions
and those underlying its behavioural responses are
still obscure.
In-vitro and in-vivo experiments illustrate the posi-
tive influence of a chronic hyperforin treatment on the
expression of TrkB. This up-regulation is observed on
cultured cortical neurons from embryonic mice (in
vitro data) as well as on brain from adult mice (in-vivo
data). The hyperforin-dependent regulation of the
gene coding for this BDNF receptor can be observed
in cultured neurons from immature brains and in vivo
on mature brains. The hyperforin-dependent ex-
pression of TrkB is abolished in the presence of the
Ca2+ channel blocker SKF-96365, is sensitive to the
Ca2+ chelator BAPTA, critically depends on the ac-
tivity of the serine-threonine PKA and involves the
inducible transcription factor CREB. Upon binding to
gene promoters p-CREB, the active form of CREB,
controls the expression of various proteins like TrkB
(Lonze & Ginty, 2002). The action of this transcription
factor involves a transcriptional co-activator, the
CREB-binding protein (CBP). It is a Zn2+-binding
protein participating in the regulation of transcription
(Legge et al. 2004; Newton et al. 2000). TPENmay block
the expression of TrkB by altering the functions and/
or the folding of this Zn2+-binding transcriptional
co-activator. Figure 5 is a schematic representation
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Fig. 3. Hyperforin enhances the expression of TrkB, CREB and p-CREB in cultured cortical neurons. Western blot analysis of
the expression of TrkB, p-TRkB, CREB and p-CREB in cortical neurons kept in culture for 72 h in the presence of 1 mM hyperforin.
(a) Representative Western blots from control neurons (x) and neurons treated with hyperforin (+). (b) Quantitative
presentation of the expression of each protein. Expression levels were normalized to the expression level of actin and are
represented in % of the expression of each protein under control conditions. Data are collected from at least three independent
experiments. * p<0.05 (Kruskal–Wallis followed by a Holm–Sidak test). (c) and (d) Western blot analysis of the expression
of p-CREB (c) and TrkB (d) in cortical neurons kept in culture for 72 h in the presence of 1 mM hyperforin without or with the
channel blocker SKF-96365 (5 mM), the Ca2+ chelator BAPTA/AM (100 nM), or the PKA inhibitor RpcAMP (20 mM). * p<0.05
(Kruskal–Wallis followed by a Holm–Sidak test). In some experiments, cortical neurons in culture were kept for 72 h with
a medium supplemented with either 1 mM TPEN or 1 mM TPEN+1 mM hyperforin.
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showing this hyperforin-dependent signalling path-
way. Some differences can be noted when comparing
the in-vivo and the in-vitro data. For instance, hy-
perforin strongly augments the expression of p-TrkB
in vivowhereas no change was observed in vitro. These
differences could be due to the different duration of
the treatment (4 wk in vivo vs. 72 h in vitro) and to the
concentrations of hyperforin used. But in both models
(adult mice chronically treated and cortical neurons in
cultures), the plant extract potently enhances the ex-
pression of TrkB.
The findings of the present report show that hy-
perforin controls a SKF-96365-sensitive signalling cas-
cade, involving PKA and CREB. TRPC6 being the only
plasma membrane channels known to date to be acti-
vated by this agent, it is proposed that they mediate
the hyperforin response. Ca2+ ions entering via hy-
perforin-sensitive TRPC6 channels seem to control, in
a PKA-dependent manner, the phosphorylation of
CREB and the downstream expression of TrkB. The
mechanism by which Ca2+ ions seem to activate PKA
in cortical neurons has not been addressed in the
present study. Ca2+ ions, via their binding to calmo-
dulin CaM, are able to activate PKA, making CREB a
Ca2+-inducible transcription factor (Lonze & Ginty,
2002). Importantly, the overexpression of TRPC6 aug-
ments the phosphorylation of CREB (Tai et al. 2008).
We propose that Ca2+ entering through TRPC6
channels, indirectly activate PKA.
In the brain of adult mice, TRPC6 channels are
present in the cortex but are, however, found at amuch
weaker level in the hippocampus where their ex-
pression is developmentally regulated (Tai et al. 2008).
Indeed, TRPC6 expression increases from P0 to P14
and then strongly decreases (Tai et al. 2008). Of note, in
the hippocampus of young mice, TRPC6 controls the
neuritic outgrowth of immature hippocampal neurons
and the formation of excitatory synapses (Tai et al.
2008; Zhou et al. 2008). Therefore, the entry of Ca2+
through TRPC6 is able to control downstream cellular
responses. Our data support this view and are perfectly
in line with reports showing that hyperforin is an acti-
vator of TRPC6 channels (Leuner et al. 2007;Muller et al.
2008). In addition, a chronic hyperforin treatment en-
hanced their expression further illustrating that TRPC6
is a target of this plant extract.
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Fig. 4. TRPC6 expression in the cortex and hippocampus of
mice adult brain. (a) Representative Western blots showing
the expression of TRPC6 and actin in the cortex and
hippocampus of control (x) and hyperforin-treated animals
(+). (b) Summary plot showing the expression of TRPC6 in
control (n=3) (black bars) and in hyperforin-treated animals
(n=3) (white bars). TRPC6 expression is expressed with
respect to actin expression. * p<0.05 (Mann–Whitney).
Duration of treatment : 4 wk.
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Fig. 5. Schematic representation showing the hyperforin-
dependent signalling pathway in the cortex. Hyperforin
activates SKF-96365-sensitive Ca2+ channels of the plasma
membrane leading to cytosolic Ca2+ changes that can be
prevented by the Ca2+ chelator BAPTA. The hyperforin-
triggered Ca2+ influx results in the activation of PKA which
phosphorylates CREB, giving rise to enhanced levels of
p-CREB. CBP mediates the interaction between the
transcription factor CREB and the DNA. CBP is a
transcriptional co-activator that possesses three regions that
bind Zn2+ ions. AC, Adenylate cyclase ; CBP, CREB-binding
protein ; PKA, protein kinase A.
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Although, a great number of studies have con-
tributed to a better understanding of the molecular
biology of depressive disorder, little is known re-
garding the precise mechanism of action of anti-
depressant drugs. According to some authors, the
neurotrophin BDNF and the action of antidepressants
on the hippocampal adult neurogenesis are two cen-
tral features involving TrkB receptors. Indeed, some
experimental data support the existence of a func-
tional link between BDNF, TrkB, the adult hippo-
campal neurogenesis and the behavioural effects of
antidepressant drugs (Li et al. 2008). According to
this model, TrkB has a central role in the pathophy-
siology of depressive disorders. Of interest, hyperforin
augments its expression. However, there is no un-
equivocal demonstration showing that the adult
hippocampal neurogenesis is really necessary to pro-
duce the behavioural effects of antidepressants (Sahay
et al. 2011). Although the BDNF–neurogenesis model
has been well documented, it is debated (DeCarolis &
Eisch, 2010 ; Sapolsky, 2004), notably because it seems
to suffer some exceptions (Bessa et al. 2009; David et al.
2009; Surget et al. 2008) suggesting that it may not fully
cover the neurobiology of all the antidepressants. First,
a decrease in hippocampal neurogenesis does not in-
duce a depressive-like behaviour, indicating that this
process is not involved in the pathogenesis of de-
pression (Revest et al. 2009; Santarelli et al. 2003).
Importantly, the effects of antidepressants on neuro-
genesis seem to depend on the mouse strain used
(Holick et al. 2008). In addition, antidepressants like
fluoxetine seem to stimulate the hippocampal neuro-
genesis of mice under chronic stress but not when
tested on unstressed animals (Surget et al. 2010).
Another important parameter to consider when trying
to understand the requirement (or not) of hippo-
campal neurogenesis in the efficacy of antidepressant
drugs, is the type of antidepressant used. For instance,
hippocampal neurogenesis underlines the action of
monoaninergic compounds but does not seem to be
required for drugs acting on the hypothalamo-
pituitary-adrenal (HPA) axis (Surget et al. 2008).
In conclusion, in-vitro and in-vivo experiments were
conducted to better address the CNS effects of the
plant extract hyperforin. The data presented show that
it controls a signalling cascade involving Ca2+-con-
ducting channels, PKA and CREB, which, in turn, up-
regulates the expression of the BDNF receptor TrkB.
Additionally, these responses are observed in the cor-
tex but not in the hippocampus of adult mice where
the expression of TRPC6 channels is weak. Altogether,
the cortex appears as an important brain structure
participating in the CNS effects of hyperforin.
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